Insights into the mechanisms of action of anti‐Aβ antibodies in Alzheimer's disease mouse models

Correlative Memory Deficits, Aβ Elevation, and Amyloid Plaques in Transgenic Mice

Hsiao, K., Chapman, P., Nilsen, S., Eckman, C., Harigaya, Y., Younkin, S., Yang, F., & Cole, G. (1996) · Science · doi:10.1126/science.274.5284.99 · Cited by 4,210 · see citing works

Diffusible, nonfibrillar ligands derived from Aβ _1–42 are potent central nervous system neurotoxins

Lambert, M. P., Barlow, A. K., Chromy, B. A., Edwards, C., Freed, R., Liosatos, M., Morgan, T. E., Rozovsky, I., Trommer, B., Viola, K. L., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6448 · Cited by 3,506 · see citing works

Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse

Schenk, D., Barbour, R., Dunn, W., Gordon, G., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., Khan, K., et al. (1999) · Nature · doi:10.1038/22124 · Cited by 3,160 · see citing works

Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

Scheuner, D., Eckman, C., Jensen, M., Song, X., Citron, M., Suzuki, N., Bird, T. D., Hardy, J., Hutton, M., Kukull, W., et al. (1996) · Nature Medicine · doi:10.1038/nm0896-864 · Cited by 2,599 · see citing works

Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

Bard, F., Cannon, C., Barbour, R., Burke, R.-L., Games, D., Grajeda, H., Guido, T., Hu, K., Huang, J., Johnson-Wood, K., et al. (2000) · Nature Medicine · doi:10.1038/78682 · Cited by 2,012 · see citing works

Natural oligomers of the amyloid-β protein specifically disrupt cognitive function

Cleary, J. P., Walsh, D. M., Hofmeister, J. J., Shankar, G. M., Kuskowski, M. A., Selkoe, D. J., & Ashe, K. H. (2004) · Nature Neuroscience · doi:10.1038/nn1372 · Cited by 1,677 · see citing works

P <scp>ROTOFIBRILS</scp> , P <scp>ORES</scp> , F <scp>IBRILS, AND</scp> N <scp>EURODEGENERATION</scp> : Separating the Responsible Protein Aggregates from The Innocent Bystanders

Caughey, B., & Lansbury, P. T. (2003) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.26.010302.081142 · Cited by 1,650 · see citing works

Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

Janus, C., Pearson, J., McLaurin, J., Mathews, P. M., Jiang, Y., Schmidt, S. D., Chishti, M. A., Horne, P., Heslin, D., French, J., et al. (2000) · Nature · doi:10.1038/35050110 · Cited by 1,431 · see citing works

Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report

Nicoll, J. A. R., Wilkinson, D., Holmes, C., Steart, P., Markham, H., & Weller, R. O. (2003) · Nature Medicine · doi:10.1038/nm840 · Cited by 1,397 · see citing works

Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization

Orgogozo, J.-M., Gilman, S., Dartigues, J.-F., Laurent, B., Puel, M., Kirby, L. C., Jouanny, P., Dubois, B., Eisner, L., Flitman, S., et al. (2003) · Neurology · doi:10.1212/01.wnl.0000073623.84147.a8 · Cited by 1,356 · see citing works

Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial

Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329 · see citing works

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works

The neuronal MAP kinase cascade: a biochemical signal integration system subserving synaptic plasticity and memory

Sweatt, J. D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00054.x · Cited by 1,131 · see citing works

Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease

Kawarabayashi, T., Younkin, L. H., Saido, T. C., Shoji, M., Ashe, K. H., & Younkin, S. G. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-02-00372.2001 · Cited by 1,053 · cited 1× · see citing works

Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain

Dovey, H. F., John, V., Anderson, J. P., Chen, L. Z., Andrieu, P. D. S. I., Fang, L. Y., Freedman, S. B., Folmer, B., Goldbach, E. G., Holsztynska, E. J., et al. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00012.x · Cited by 870 · see citing works

Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model

Dodart, J.-C., Bales, K. R., Gannon, K. S., Greene, S. J., DeMattos, R. B., Mathis, C., DeLong, C. A., Wu, S., Wu, X., Holtzman, D. M., et al. (2002) · Nature Neuroscience · doi:10.1038/nn842 · Cited by 858 · see citing works

Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer’s disease

Georganopoulou, D. G., Chang, L., Nam, J.-M., Thaxton, C. S., Mufson, E. J., Klein, W. L., & Mirkin, C. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409336102 · Cited by 835 · see citing works

Antibodies against β-Amyloid Slow Cognitive Decline in Alzheimer's Disease

Höck, C., Konietzko, U., Streffer, J. R., Tracy, J., Signorell, A., Müller-Tillmanns, B., Lemke, U., Henke, K., Moritz, E., Garcia, E., et al. (2003) · Neuron · doi:10.1016/s0896-6273(03)00294-0 · Cited by 777 · see citing works

Human amyloid-β synthesis and clearance rates as measured in cerebrospinal fluid in vivo

Bateman, R. J., Munsell, L. Y., Morris, J. C., Swarm, R., Yarasheski, K. E., & Holtzman, D. M. (2006) · Nature Medicine · doi:10.1038/nm1438 · Cited by 599 · see citing works

Brain to Plasma Amyloid-β Efflux: a Measure of Brain Amyloid Burden in a Mouse Model of Alzheimer's Disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Paul, S. M., & Holtzman, D. M. (2002) · Science · doi:10.1126/science.1067568 · Cited by 563 · see citing works

Effects of Aβ immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease

Fox, N. C., Black, R. S., Gilman, S., Rossor, M. N., Griffith, S. G., Jenkins, L., & Koller, M. (2005) · Neurology · doi:10.1212/01.wnl.0000159743.08996.99 · Cited by 550 · see citing works

Amyloid-β oligomers: their production, toxicity and therapeutic inhibition

Walsh, D. M., Klyubin, I. V., Fadeeva, J. V., Rowan, M. J., & Selkoe, D. J. (2002) · Biochemical Society Transactions · doi:10.1042/bst0300552 · Cited by 507 · see citing works

Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning

Schenk, D. (2002) · Nature Reviews Neuroscience · doi:10.1038/nrn938 · Cited by 436 · see citing works

Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology

Bard, F., Barbour, R., Cannon, C., Carretto, R., Fox, M., Games, D., Guido, T., Hoenow, K., Hu, K., Johnson-Wood, K., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436286100 · Cited by 411 · see citing works

<i>In Vivo</i> Assessment of Brain Interstitial Fluid with Microdialysis Reveals Plaque-Associated Changes in Amyloid-β Metabolism and Half-Life

Cirrito, J. R., May, P. C., O'Dell, M. A., Taylor, J. W., Parsadanian, M., Cramer, J. W., Audia, J. E., Nissen, J. S., Bales, K. R., Paul, S. M., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-26-08844.2003 · Cited by 394 · see citing works

Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease

Masliah, E., Hansen, L., Adame, A., Crews, L. A., Bard, F., Lee, C., Seubert, P. A., Games, D., Kirby, L., & Schenk, D. (2005) · Neurology · doi:10.1212/01.wnl.0000148590.39911.df · Cited by 355 · see citing works

Amyloid β-Peptide Is Transported on Lipoproteins and Albumin in Human Plasma

Biere, A. L., Ostaszewski, B., Stimson, E. R., Hyman, B. T., Maggio, J. E., & Selkoe, D. J. (1996) · Journal of Biological Chemistry · doi:10.1074/jbc.271.51.32916 · Cited by 331 · see citing works

Novel Therapeutic Approach for the Treatment of Alzheimer's Disease by Peripheral Administration of Agents with an Affinity to β-Amyloid

Matsuoka, Y., Saito, M., LaFrancois, J. J., Saito, M., Gaynor, K., Olm, V., Wang, L., Casey, E., Lu, Y., Shiratori, C., et al. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00029.2003 · Cited by 324 · see citing works

Non-Fc-Mediated Mechanisms Are Involved in Clearance of Amyloid-β<i>In Vivo</i>by Immunotherapy

Bacskai, B. J., Kajdasz, S. T., McLellan, M. E., Games, D., Seubert, P., Schenk, D., & Hyman, B. T. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-18-07873.2002 · Cited by 323 · see citing works

Intravenous immunoglobulins containing antibodies against -amyloid for the treatment of Alzheimer's disease

Dodel, R. C. (2004) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.2003.033399 · Cited by 317 · see citing works

Passive Amyloid Immunotherapy Clears Amyloid and Transiently Activates Microglia in a Transgenic Mouse Model of Amyloid Deposition

Wilcock, D. M., Rojiani, A. M., Rosenthal, A., Levkowitz, G., Subbarao, S., Alamed, J., Wilson, D. H., Wilson, N., Freeman, M. J., Gordon, M. N., et al. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.1090-04.2004 · Cited by 298 · see citing works

Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease

Höck, C., Konietzko, U., Papassotiropoulos, A., Wollmer, A., Streffer, J. R., von Rotz, R. C., Davey, G. E., Moritz, E., & Nitsch, R. M. (2002) · Nature Medicine · doi:10.1038/nm783 · Cited by 281 · see citing works

Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice

Sigurdsson, E. M., Scholtzova, H., Mehta, P. D., Frangione, B., & Wısnıewskı, T. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)61715-4 · Cited by 258 · see citing works

Targeting Amyloid-β Peptide (Aβ) Oligomers by Passive Immunization with a Conformation-selective Monoclonal Antibody Improves Learning and Memory in Aβ Precursor Protein (APP) Transgenic Mice

Lee, E. B., Leng, L. Z., Zhang, B., Kwong, L. K., Trojanowski, J. Q., Abel, T. G., & Lee, V. M. ‐. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m511018200 · Cited by 252 · see citing works

IgG-Assisted Age-Dependent Clearance of Alzheimer's Amyloid β Peptide by the Blood–Brain Barrier Neonatal Fc Receptor

Deane, R., Sagare, A. P., Hamm, K., Parisi, M., LaRue, B., Guo, H., Wu, Z., Holtzman, D. M., & Zloković, B. V. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.3697-05.2005 · Cited by 233 · see citing works

Intracranially Administered Anti-Αβ Antibodies Reduce β-Amyloid Deposition by Mechanisms Both Independent of and Associated with Microglial Activation

Wilcock, D. M., DiCarlo, G., Henderson, D., Jackson, J., Clarke, K., Ugen, K. E., Gordon, M. N., & Morgan, D. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-09-03745.2003 · Cited by 232 · see citing works

Amyloid-β Peptides Interact with Plasma Proteins and Erythrocytes: Implications for Their Quantitation in Plasma

Kuo, Y.-M., Kokjohn, T. A., Kalback, W., Luehrs, D., Galasko, D. R., Chevallier, N., Koo, E. H., Emmerling, M. R., & Roher, A. E. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2222 · Cited by 230 · see citing works

Safety, Tolerability, and Changes in Amyloid β Concentrations After Administration of a γ-Secretase Inhibitor in Volunteers

Siemers, E., Skinner, M., Dean, R. A., Gonzales, C., Satterwhite, J. H., Farlow, M. R., NESS, D. K., & May, P. C. (2005) · Clinical Neuropharmacology · doi:10.1097/01.wnf.0000167360.27670.29 · Cited by 214 · see citing works

Amyloid-β Immunization Effectively Reduces Amyloid Deposition in FcRγ-/-Knock-Out Mice

Das, P., HOWARD, V. G., Loosbrock, N., Dickson, D. W., Murphy, M. P., & Golde, T. E. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-24-08532.2003 · Cited by 212 · see citing works

Systemic Catabolism of Alzheimer's Aβ40 and Aβ42

Ghiso, J., Shayo, M., Calero, M., Ng, D., Tomidokoro, Y., Gandy, S., Rostagno, A., & Frangione, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m407668200 · Cited by 209 · see citing works

Anti-A 42- and anti-A 40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model

Levites, Y. (2005) · Journal of Clinical Investigation · doi:10.1172/jci25410 · Cited by 207 · see citing works

Reversible in vitro growth of Alzheimer disease beta-amyloid plaques by deposition of labeled amyloid peptide.

Maggio, J. E., Stimson, E. R., Ghilardi, J. R., Allen, C. J., Dahl, C. E., Whitcomb, D. C., Vigna, S. R., Vinters, H. V., Labenski, M. E., & Mantyh, P. W. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.12.5462 · Cited by 194 · see citing works

Anti-Aβ antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice

Brendza, R. P., Bacskai, B. J., Cirrito, J. R., Simmons, K. A., Skoch, J. M., Klunk, W. E., Mathis, C. A., Bales, K. R., Paul, S. M., Hyman, B. T., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci23269 · Cited by 190 · see citing works

Morphological Characterization of Thioflavin-S-Positive Amyloid Plaques in Transgenic Alzheimer Mice and Effect of Passive Aβ Immunotherapy on Their Clearance

Bussière, T., Bard, F., Barbour, R., Grajeda, H., Guido, T., Khan, K., Schenk, D., Games, D., Seubert, P. A., & Buttini, M. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63360-3 · Cited by 169 · see citing works

Alzheimer disease therapy: Can the amyloid cascade be halted?

Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17527 · Cited by 164 · see citing works

Reduced effectiveness of Aβ1-42 immunization in APP transgenic mice with significant amyloid deposition

Das, P., Murphy, M. P., Younkin, L. H., Younkin, S. G., & Golde, T. E. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00245-7 · Cited by 150 · see citing works

Alzheimer disease therapy: Can the amyloid cascade be halted?

Golde, T. E. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317527 · Cited by 139 · see citing works

Aβ42 immunization in Alzheimer's disease generates Aβ N-terminal antibodies

Lee, M., Bard, F., Johnson‐Wood, K., Lee, C., Hu, K., Griffith, S. G., Black, R. S., Schenk, D., & Seubert, P. A. (2005) · Annals of Neurology · doi:10.1002/ana.20592 · Cited by 129 · see citing works

Binding of Gelsolin, a Secretory Protein, to Amyloid β-Protein

Chauhan, V. P. S., Ray, I., Chauhan, A., & Wı́sniewski, H. M. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.0623 · Cited by 97 · see citing works

Number of A β Inoculations in APP+PS1 Transgenic Mice Influences Antibody Titers, Microglial Activation, and Congophilic Plaque Levels

Wilcock, D. M., Gordon, M. N., Ugen, K. E., Gottschall, P. E., DiCarlo, G., Dickey, C. A., Boyett, K. W., Jantzen, P. T., Connor, K. E., Melachrino, J., et al. (2001) · DNA and Cell Biology · doi:10.1089/10445490152717596 · Cited by 87 · see citing works

Apolipoprotein E influences amyloid-beta clearance from the murine periphery

Hone, E., Martins, I., Fonte, J., & Martins, R. N. (2003) · Journal of Alzheimer's Disease · doi:10.3233/jad-2003-5101 · Cited by 78 · see citing works

Intravascular infusions of soluble β-amyloid compromise the blood–brain barrier, activate CNS glial cells and induce peripheral hemorrhage

Su, G. C., Arendash, G. W., Kalaria, R. N., Bjugstad, K. B., & MULLAN, M. J. (1999) · Brain Research · doi:10.1016/s0006-8993(98)01143-3 · Cited by 69 · see citing works

Lack of Specific Amyloid-β(1-42) Suppression by Nonsteroidal Anti-Inflammatory Drugs in Young, Plaque-Free Tg2576 Mice and in Guinea Pig Neuronal Cultures

Lanz, T. A., Fici, G. J., & Merchant, K. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.073965 · Cited by 66 · see citing works

Spontaneous Aggregation and Cytotoxicity of the β-Amyloid Aβ1–40: A Kinetic Model

Taylor, B. M., Sarver, R. W., Fici, G. J., Poorman, R. A., Lutzke, B. S., Molinari, A., Kawabe, T. T., Kappenman, K., Buhl, A. E., & Epps, D. E. V. (2003) · Journal of Protein Chemistry · doi:10.1023/a:1023063626770 · Cited by 47 · see citing works

The F(ab′)2 fragment of an Aβ-specific monoclonal antibody reduces Aβ deposits in the brain

Tamura, Y., Hamajima, K., Matsui, K., Yanoma, S., Narita, M., Tajima, N., Xin, K.-Q., Klinman, D. M., & Okuda, K. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.04.007 · Cited by 37 · see citing works

The bulk of endogenously produced IgG2a is eliminated from the serum of adult C57BL/6 mice with a half‐life of 6–8 days

Vieira, P., & Rajewsky, K. (1986) · European Journal of Immunology · doi:10.1002/eji.1830160727 · Cited by 33 · see citing works

Risk Factors Associated With β-Amyloid(1-42) Immunotherapy in Preimmunization Gene Expression Patterns of Blood Cells

O’Toole, M. (2005) · Archives of Neurology · doi:10.1001/archneur.62.10.1531 · Cited by 29 · see citing works

Effects of a behaviorally active antibody on the brain uptake and clearance of amyloid beta proteins

Banks, W. A., Pagliari, P., Nakaoke, R., & Morley, J. E. (2004) · Peptides · doi:10.1016/j.peptides.2004.09.016 · Cited by 26 · see citing works

β‐Amyloid Vasoactivity and Proinflammation in Microglia Can Be Blocked by cGMP‐Elevating Agents

Paris, D., Town, T., Parker, T. A., Humphrey, J., & MULLAN, M. J. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06397.x · Cited by 22 · see citing works

A technique for the collection of cerebrospinal fluid from mice.

Vogelweid, C. M., & Kier, A. B. (1988) · PubMed · Cited by 14 · see citing works

Open peer commentary regarding Aβ immunization and CNS inflammation by Pasinetti et al.

DAS, P., & Golde, T. E. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00031-3 · Cited by 10 · see citing works

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

Sevigny, J., Chiao, P., Bussière, T., Weinreb, P. H., Williams, L., Maier, M., Dunstan, R., Salloway, S., Chen, T., Ling, Y., et al. (2016) · Nature · doi:10.1038/nature19323 · Cited by 3,059 · see citing works

Survey of the year 2003 commercial optical biosensor literature

Rich, R. L., & Myszka, D. G. (2004) · Journal of Molecular Recognition · doi:10.1002/jmr.726 · Cited by 505 · see citing works

Gantenerumab: A Novel Human Anti-Aβ Antibody Demonstrates Sustained Cerebral Amyloid-β Binding and Elicits Cell-Mediated Removal of Human Amyloid-β

Bohrmann, B., Baumann, K., Benz, J., Gerber, F., Huber, W., Knoflach, F., Messer, J., Oroszlan, K., Rauchenberger, R., Richter, W. F., et al. (2012) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110977 · Cited by 448 · see citing works

Tau Aggregation and Its Interplay with Amyloid-β

Nisbet, R. M., Polanco, J.-C., Ittner, L. M., & Götz, J. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1371-2 · Cited by 359 · see citing works

Advancing translational research with the Semantic Web

Ruttenberg, A., Clark, T., Bug, W., Samwald, M., Bodenreider, O., Chen, H., Doherty, D. W., Forsberg, K., Gao, Y. C., Kashyap, V., et al. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-s3-s2 · Cited by 330 · see citing works

18-Month study of intravenous immunoglobulin for treatment of mild Alzheimer disease

Relkin, N. R., Szabo, P., Adamiak, B., Burgut, T., Monthé, C., Lent, R. W., Younkin, S. G., Younkin, L. H., Schiff, R. I., & Weksler, M. E. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.12.021 · Cited by 305 · see citing works

Role of LRP1 in the pathogenesis of Alzheimer's disease: evidence from clinical and preclinical studies

Shinohara, M., Tachibana, M., Kanekiyo, T., & Bu, G. (2017) · Journal of Lipid Research · doi:10.1194/jlr.r075796 · Cited by 297 · see citing works

Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles

Castillo-Carranza, D. L., Sengupta, U., Guerrero-Muñoz, M. J., Lasagna-Reeves, C. A., Gerson, J. E., Singh, G., Estes, D. M., Barrett, A. D. T., Dineley, K. T., Jackson, G. R., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.3192-13.2014 · Cited by 278 · see citing works

Ultrasound treatment of neurological diseases — current and emerging applications

Leinenga, G., Langton, C. M., Nisbet, R. M., & Götz, J. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.13 · Cited by 271 · see citing works

Inhibition of Amyloid Formation

Härd, T., & Lendel, C. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2011.12.062 · Cited by 266 · see citing works

Immunotherapy for Alzheimer’s disease: Key Symposium: Immunotherapy for Alzheimer’s disease

Morgan, D. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02315.x · Cited by 225 · see citing works

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease

Britschgi, M., Olin, C. E., Johns, H. T., Takeda-Uchimura, Y., LeMieux, M. C., Rufibach, K., Rajadas, J., Zhang, H., Tomooka, B., Robinson, W. H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0904866106 · Cited by 201 · see citing works

Brain Bioavailability of Human Intravenous Immunoglobulin and its Transport through the Murine Blood–Brain Barrier

St‐Amour, I., Paré, I., Alata, W., Coulombe, K., Goulet, C. R., Drouin‐Ouellet, J., Vandal, M., Soulet, D., Bazin, R., & Calon, F. (2013) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/jcbfm.2013.160 · Cited by 190 · see citing works

Combined effects of scanning ultrasound and a tau-specific single chain antibody in a tau transgenic mouse model

Nisbet, R. M., Van der Jeugd, A., Leinenga, G., Evans, H. T., Janowicz, P. W., & Götz, J. (2017) · Brain · doi:10.1093/brain/awx052 · Cited by 187 · see citing works

Genetic Suppression of Transgenic APP Rescues Hypersynchronous Network Activity in a Mouse Model of Alzeimer's Disease

Born, H. A., Kim, J.-Y., Savjani, R. R., Das, P., Dabaghian, Y. A., Guo, Q., Yoo, J. W., Schuler, D. R., Cirrito, J. R., Zheng, H., et al. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.5171-13.2014 · Cited by 178 · see citing works

Stigmasterol attenuates inflammatory response of microglia via NF-κB and NLRP3 signaling by AMPK activation

Jie, F., Yang, X., Yang, B., Liu, Y., Wu, L., & Lu, B. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113317 · Cited by 159 · see citing works

Age-related decline in immunity: implications for vaccine responsiveness

Kumar, R., & Burns, E. A. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.4.467 · Cited by 156 · see citing works

Involvement of Fc Receptors in Disorders of the Central Nervous System

Okun, E., Mattson, M. P., & Arumugam, T. V. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8099-5 · Cited by 142 · see citing works

Intracranial Adeno-Associated Virus-Mediated Delivery of Anti-Pan Amyloid β, Amyloid β40, and Amyloid β42 Single-Chain Variable Fragments Attenuates Plaque Pathology in Amyloid Precursor Protein Mice

Levites, Y., Jansen, K. R., Smithson, L. A., Dakin, R. S., Holloway, V. M., Das, P., & Golde, T. E. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.2795-06.2006 · Cited by 128 · see citing works

Immunotherapy for Alzheimer‘s Disease: From Anti-β-Amyloid to Tau-Based Immunization Strategies

Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., Greco, A., Seripa, D., & Pilotto, A. (2012) · Immunotherapy · doi:10.2217/imt.11.170 · Cited by 125 · see citing works

Intracerebroventricular amyloid-β antibodies reduce cerebral amyloid angiopathy and associated micro-hemorrhages in aged Tg2576 mice

Thakker, D. R., Weatherspoon, M. R., Harrison, J., Keene, T. E., Lane, D. S., Kaemmerer, W. F., Stewart, G. R., & Shafer, L. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813404106 · Cited by 124 · see citing works

Disease-Modifying Therapies for Alzheimer’s Disease: More Questions than Answers

Golde, T. E. (2022) · Neurotherapeutics · doi:10.1007/s13311-022-01201-2 · Cited by 119 · see citing works

Robust amyloid clearance in a mouse model of Alzheimer’s disease provides novel insights into the mechanism of amyloid-β immunotherapy

Wang, A., Das, P., Switzer, R. C., Golde, T. E., & Jankowsky, J. L. (2011) · The Journal of Neuroscience · doi:10.1523/jneurosci.5077-10.2011 · Cited by 118 · see citing works

Disease modifying therapy for AD?¹

Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117 · see citing works

Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117 · see citing works

Survey of the year 2006 commercial optical biosensor literature

Rich, R. L., & Myszka, D. G. (2007) · Journal of Molecular Recognition · doi:10.1002/jmr.862 · Cited by 111 · see citing works

Natural human antibodies to amyloid beta peptide

Szabo, P., Relkin, N. R., & Weksler, M. E. (2008) · Autoimmunity Reviews · doi:10.1016/j.autrev.2008.03.007 · Cited by 107 · see citing works

A highly insoluble state of Aβ similar to that of Alzheimer's disease brain is found in Arctic APP transgenic mice

Philipson, O., Hammarström, P., Nilsson, K. P. R., Portelius, E., Olofsson, T., Ingelsson, M., Hyman, B. T., Blennow, K., Lannfelt, L., Kalimo, H., et al. (2008) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.11.022 · Cited by 106 · see citing works

Delivery of immunoglobulin G antibodies to the rat nervous system following intranasal administration: Distribution, dose-response, and mechanisms of delivery

Kumar, N. N., Lochhead, J. J., Pizzo, M. E., Nehra, G., Boroumand, S., Greene, G., & Thorne, R. G. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.08.006 · Cited by 95 · see citing works

Targeting Aβ and tau in Alzheimer's disease, an early interim report

Golde, T. E., Petrucelli, L., & Lewis, J. (2010) · Experimental Neurology · doi:10.1016/j.expneurol.2009.07.035 · Cited by 89 · see citing works

Exposure Levels of Anti-LINGO-1 Li81 Antibody in the Central Nervous System and Dose-Efficacy Relationships in Rat Spinal Cord Remyelination Models after Systemic Administration

Pepinsky, R. B., Shao, Z., Ji, B., Wang, Q., Meng, G., Walus, L. R., Lee, X., Hu, Y., Graff, C. P., Garber, E. A., et al. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.183483 · Cited by 87 · see citing works

Open questions for Alzheimer’s disease immunotherapy

Golde, T. E. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt233 · Cited by 85 · see citing works

Genetics of CD33 in Alzheimer's disease and acute myeloid leukemia

Malik, M., Chiles, J. W., Xi, H. S., Medway, C., Simpson, J. F., Potluri, S., Howard, D. S., Yu, L., Paumi, C. M., Mukherjee, S., et al. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv092 · Cited by 82 · see citing works

Targeting Malignant Brain Tumors with Antibodies

Razpotnik, R., Novak, N., Šerbec, V. Č., & Rajčević, U. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01181 · Cited by 79 · see citing works

TLR5 decoy receptor as a novel anti-amyloid therapeutic for Alzheimer’s disease

Chakrabarty, P., Li, A., Ladd, T. B., Strickland, M. R., Koller, E. J., Burgess, J. D., Funk, C. C., Cruz, P. E., Allen, M., Yaroshenko, M., et al. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20180484 · Cited by 78 · see citing works

Ultrasound-mediated blood-brain barrier opening enhances delivery of therapeutically relevant formats of a tau-specific antibody

Janowicz, P. W., Leinenga, G., Götz, J., & Nisbet, R. M. (2019) · Scientific Reports · doi:10.1038/s41598-019-45577-2 · Cited by 76 · see citing works

Systemic vaccination with anti‐oligomeric monoclonal antibodies improves cognitive function by reducing Aβ deposition and tau pathology in 3xTg‐AD mice

Rasool, S., Martínez‐Coria, H., Wu, J., LaFerla, F. M., & Glabe, C. G. (2013) · Journal of Neurochemistry · doi:10.1111/jnc.12305 · Cited by 74 · see citing works

Chronic Intranasal Treatment with an Anti-Aβ30-42 scFv Antibody Ameliorates Amyloid Pathology in a Transgenic Mouse Model of Alzheimer's Disease

Cattepoel, S., Hanenberg, M., Kulic, L., & Nitsch, R. M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0018296 · Cited by 73 · see citing works

Beta‐amyloid protein (25–35) disrupts hippocampal network activity: Role of Fyn‐kinase

Peña‐Ortega, F., Ordaz, B., Balleza‐Tapia, H., Bernal‐Pedraza, R., Márquez‐Ramos, A., Carmona‐Aparicio, L., & Giòrdano, M. (2009) · Hippocampus · doi:10.1002/hipo.20592 · Cited by 71 · see citing works

Safety and Efficacy of Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: A Systematic Review and Meta-Analysis

Penninkilampi, R., Brothers, H. M., & Eslick, G. D. (2016) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-016-9722-5 · Cited by 69 · see citing works

Engineering and Pharmacology of Blood–Brain Barrier-Permeable Bispecific Antibodies

Stanimirovic, D. B., Kemmerich, K., Haqqani, A. S., & Farrington, G. K. (2014) · Advances in pharmacology · doi:10.1016/bs.apha.2014.06.005 · Cited by 68 · see citing works

Transgenic APP expression during postnatal development causes persistent locomotor hyperactivity in the adult

Rodgers, S. P., Born, H. A., Das, P., & Jankowsky, J. L. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-28 · Cited by 67 · see citing works

Perispinal etanercept: Potential as an Alzheimer therapeutic

Griffin, W. S. T. (2008) · Journal of Neuroinflammation · doi:10.1186/1742-2094-5-3 · Cited by 66 · see citing works

Safety and Efficacy of Scanning Ultrasound Treatment of Aged APP23 Mice

Leinenga, G., & Götz, J. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00055 · Cited by 64 · see citing works

Enhanced Proteolytic Clearance of Plasma Aβ by Peripherally Administered Neprilysin Does Not Result in Reduced Levels of Brain Aβ in Mice

Walker, J. R., Pacoma, R., Watson, J., Ou, W., Alves, J., Mason, D. E., Peters, E. C., Urbina, H. D., Welzel, G., Althage, A., et al. (2013) · Journal of Neuroscience · doi:10.1523/jneurosci.3407-12.2013 · Cited by 58 · see citing works

Antibody-based therapy in Alzheimer's disease

Pul, R., Dodel, R. C., & Stangel, M. (2011) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2011.552884 · Cited by 58 · see citing works

Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches

Kumar, N. N., Pizzo, M. E., Nehra, G., Wilken-Resman, B., Boroumand, S., & Thorne, R. G. (2018) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.8b00548 · Cited by 57 · see citing works

The stress response neuropeptide CRF increases amyloid‐β production by regulating γ‐secretase activity

Park, H., Ran, Y., Jung, J. I., Holmes, O. W., Price, A. R., Smithson, L. A., Ceballos‐Diaz, C., Han, C. J., Wolfe, M. S., Daaka, Y., et al. (2015) · The EMBO Journal · doi:10.15252/embj.201488795 · Cited by 56 · see citing works

Cyclic Peptides as Inhibitors of Amyloid Fibrillation

Luo, J., & Abrahams, J. P. (2014) · Chemistry - A European Journal · doi:10.1002/chem.201304253 · Cited by 55 · see citing works

Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency

Agadjanyan, M. G., Zagorski, K., Petrushina, I., Davtyan, H., Kazarian, K., Antonenko, M., Davis, J. L., Bon, C., Blurton-Jones, M. M., Cribbs, D. H., et al. (2017) · Molecular Neurodegeneration · doi:10.1186/s13024-017-0172-1 · Cited by 53 · see citing works

Biodistribution of [125I]-labeled therapeutic proteins: Application in protein drug development beyond oncology**All authors are current or former employees of Wyeth, Inc.

Vugmeyster, Y., DeFranco, D., Szklut, P., Wang, Q. L., & Xu, X. (2009) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.21855 · Cited by 52 · see citing works

Complex Pharmacokinetics of a Humanized Antibody Against Human Amyloid Beta Peptide, Anti-Abeta Ab2, in Nonclinical Species

Vugmeyster, Y., Szklut, P., Wensel, D. L., Ross, J. E., Xu, X., Awwad, M., Gill, D. S., Tchistiakov, L., & Warner, G. L. (2011) · Pharmaceutical Research · doi:10.1007/s11095-011-0405-x · Cited by 50 · see citing works

Experimental Investigation of Antibody-Mediated Clearance Mechanisms of Amyloid-β in CNS of Tg-SwDI Transgenic Mice

Vasilevko, V., Xu, F., Previti, M. L., Nostrand, W. E. V., & Cribbs, D. H. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.2788-07.2007 · Cited by 48 · see citing works

AAV‐mediated delivery of an anti‐BACE1 VHH alleviates pathology in an Alzheimer's disease model

Marino, M., Zhou, L., Rincón, M. Y., Callaerts‐Vegh, Z., Verhaert, J., Wahis, J., Creemers, E., Yshii, L., Wierda, K. D. B., Saito, T., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.201809824 · Cited by 45 · see citing works

Non-Invasive Delivery of Therapeutics into the Brain: The Potential of Aptamers for Targeted Delivery

Bukari, B. A., Samarasinghe, R. M., Noibanchong, J., & Shigdar, S. L. (2020) · Biomedicines · doi:10.3390/biomedicines8050120 · Cited by 44 · see citing works

Effects of human intravenous immunoglobulin on amyloid pathology and neuroinflammation in a mouse model of Alzheimer’s disease

Puli, L., Pomeshchik, Y., Olas, K., Malm, T., Koıstınaho, J., & Tanila, H. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-105 · Cited by 43 · see citing works

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: Polymorphisms, structure, and function of complement receptor 1

Johansson, J. U., Brubaker, W. D., Javitz, H. S., Bergen, A. W., Nishita, D., Trigunaite, A., Crane, A., Ceballos, J., Mastroeni, D., Tenner, A. J., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.003 · Cited by 43 · see citing works

Anti-tau scFvs Targeted to the Cytoplasm or Secretory Pathway Variably Modify Pathology and Neurodegenerative Phenotypes

Goodwin, M. S., Sinyavskaya, O., Burg, F., O’Neal, V., Ceballos‐Diaz, C., Cruz, P. E., Lewis, J. M., Giasson, B. I., Davies, P., Golde, T. E., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.10.007 · Cited by 42 · see citing works

Fc effector of anti-Aβ antibody induces synapse loss and cognitive deficits in Alzheimer’s disease-like mouse model

Sun, X., Yu, X., Zhu, J., Li, L.-J., Zhang, L., Huang, Y., Liu, D., Ji, M., Sun, X., Zhang, L. L., et al. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01273-8 · Cited by 39 · see citing works

Focused Ultrasound Mediated Opening of the Blood-Brain Barrier for Neurodegenerative Diseases

Fishman, P. S., & Fischell, J. M. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.749047 · Cited by 38 · see citing works

Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds

Joseph‐Mathurin, N., Dorieux, O., Trouche, S. G., Boutajangout, A., Kraska, A., Fontès, P., Verdier, J., Sigurdsson, E. M., Mestre‐Francés, N., & Dhénain, M. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.05.013 · Cited by 37 · see citing works

Is passive immunization for Alzheimer's disease ‘alive and well’ or ‘dead and buried’?

Jicha, G. A. (2009) · Expert Opinion on Biological Therapy · doi:10.1517/14712590902828285 · Cited by 37 · see citing works

Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases

Benn, C., Gibson, K. R., & Reynolds, D. S. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200421 · Cited by 35 · see citing works

Peripheral complement interactions with amyloid β peptide in Alzheimer's disease: 2. Relationship to amyloid β immunotherapy

Crane, A., Brubaker, W. D., Johansson, J. U., Trigunaite, A., Ceballos, J., Bradt, B. M., Glavis‐Bloom, C., Wallace, T. L., Tenner, A. J., & Rogers, J. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.04.015 · Cited by 34 · see citing works

Alzheimer amyloid-β- peptide disrupts membrane localization of glucose transporter 1 in astrocytes: implications for glucose levels in brain and blood

Hendrix, R. D., Ou, Y., Davis, J. E., Odle, A. K., Groves, T. R., Allen, A. R., Childs, G. V., & Barger, S. W. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.10.001 · Cited by 33 · see citing works

Interpreting Alzheimer’s disease clinical trials in light of the effects on amyloid-β

Toyn, J. H., & Ahlijanian, M. K. (2014) · Alzheimer s Research & Therapy · doi:10.1186/alzrt244 · Cited by 31 · see citing works

Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine

Kabir, M. T., Uddin, M. S., Mathew, B., Das, P. K., Perveen, A., & Ashraf, G. M. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200422105156 · Cited by 31 · see citing works

Overcoming translational barriers impeding development of Alzheimer's disease modifying therapies

Golde, T. E. (2016) · Journal of Neurochemistry · doi:10.1111/jnc.13583 · Cited by 28 · see citing works

Immunotherapy in Alzheimer's Disease: Where Do We Stand? Where Should We Go?

Rommy von Bernhardi, M. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-1248 · Cited by 28 · see citing works

Cognitive Enhancers (Nootropics). Part 3: Drugs Interacting with Targets other than Receptors or Enzymes. Disease-modifying Drugs

Froestl, W., Pfeifer, A., & Muhs, A. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121729 · Cited by 27 · see citing works

Intracerebral but Not Peripheral Infection of Live Porphyromonas gingivalis Exacerbates Alzheimer’s Disease Like Amyloid Pathology in APP-TgCRND8 Mice

Aravindraja, C., Ravi, S., Liu, X., Goodwin, M. S., Veena, P., Godovikova, V., Fenno, J. C., Levites, Y., Golde, T. E., & Kesavalu, L. N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063328 · Cited by 26 · see citing works

A short perspective on the long road to effective treatments for Alzheimer's disease

Reynolds, D. S. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14581 · Cited by 26 · see citing works

Structure of the LINGO-1–Anti-LINGO-1 Li81 Antibody Complex Provides Insights into the Biology of LINGO-1 and the Mechanism of Action of the Antibody Therapy

Pepinsky, R. B., Arndt, J. W., Quan, C., Gao, Y. L., Quintero‐Monzon, O., Lee, X., & Mi, S. (2014) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.113.211771 · Cited by 25 · see citing works

Oligomeric tau-targeted immunotherapy in Tg4510 mice

Schroeder, S. K., Joly‐Amado, A., Soliman, A. S., Sengupta, U., Kayed, R., Gordon, M. N., & Morgan, D. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0274-6 · Cited by 24 · see citing works

Diagnosis of Glioblastoma by Immuno-Positron Emission Tomography

Ruiz-López, E., Calatayud-Pérez, J., Castells-Yus, I., Gimeno-Peribáñez, M. J., Calvo, N. M., Morcillo, M. Á., & Schuhmacher, A. J. (2021) · Cancers · doi:10.3390/cancers14010074 · Cited by 24 · see citing works

Ultrasound-mediated delivery of novel tau-specific monoclonal antibody enhances brain uptake but not therapeutic efficacy

Bajracharya, R., Cruz, E., Götz, J., & Nisbet, R. M. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.07.026 · Cited by 24 · see citing works

Clinical immunologic approaches for the treatment of Alzheimer's disease

Solomon, B. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.6.819 · Cited by 22 · see citing works

Limited Clearance of Pre-Existing Amyloid Plaques After Intracerebral Injection of Aβ Antibodies in Two Mouse Models of Alzheimer Disease

Tucker, S. M. F., Borchelt, D., & Troncoso, J. C. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31815f38d2 · Cited by 22 · see citing works

Amyloid-β Peptide-specific DARPins as a Novel Class of Potential Therapeutics for Alzheimer Disease

Hanenberg, M., McAfoose, J., Kulic, L., Welt, T., Wirth, F., Parizek, P., Strobel, L., Cattepoel, S., Späni, C. B., Derungs, R., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.564013 · Cited by 21 · see citing works

A Human Monoclonal IgG That Binds Aβ Assemblies and Diverse Amyloids Exhibits Anti-Amyloid ActivitiesIn VitroandIn Vivo

Levites, Y., O’Nuallain, B., Puligedda, R. D., Ondrejčák, T., Adekar, S. P., Chen, C. S., Cruz, P. E., Rosario, A. M., Macy, S. D., Mably, A. J., et al. (2015) · Journal of Neuroscience · doi:10.1523/jneurosci.5109-14.2015 · Cited by 21 · see citing works

Messenger RNA-encoded antibody approach for targeting extracellular and intracellular tau

Wongsodirdjo, P., Caruso, A. C., Yong, A., Lester, M. A., Vella, L. J., Hung, Y. H., & Nisbet, R. M. (2024) · Brain Communications · doi:10.1093/braincomms/fcae100 · Cited by 20 · see citing works

Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer’s disease

Lozupone, M., Dibello, V., Sardone, R., Castellana, F., Zupo, R., Lampignano, L., Bortone, I., Stallone, R., Altamura, M., Bellomo, A., et al. (2024) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2024.2348142 · Cited by 19 · see citing works

Anti-Aβ single-chain variable fragment antibodies exert synergistic neuroprotective activities inDrosophilamodels of Alzheimer's disease

Fernández-Fúnez, P., Zhang, Y., Sanchez-Garcia, J., de Mena, L., Khare, S., Golde, T. E., Levites, Y., & Rincón-Limas, D. E. (2015) · Human Molecular Genetics · doi:10.1093/hmg/ddv321 · Cited by 19 · see citing works

Anti-Aβ single-chain variable fragment antibodies restore memory acquisition in a Drosophila model of Alzheimer’s disease

Martín‐Peña, A., Rincón-Limas, D. E., & Fernández-Fúnez, P. (2017) · Scientific Reports · doi:10.1038/s41598-017-11594-2 · Cited by 18 · see citing works

Combination anti-Aβ treatment maximizes cognitive recovery and rebalances mTOR signaling in APP mice

Chiang, A. C. A., Fowler, S., Savjani, R. R., Hilsenbeck, S. G., Wallace, C. E., Cirrito, J. R., Das, P., & Jankowsky, J. L. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20171484 · Cited by 18 · see citing works

Anti-Tau Antibodies: Hitting the Target

Golde, T. E., Lewis, J. M., & McFarland, N. R. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.009 · Cited by 17 · see citing works

Dietary Intake of Rosmarinic Acid Increases Serum Inhibitory Activity in Amyloid A Aggregation and Suppresses Deposition in the Organs of Mice

Lin, X., Watanabe, K., Kuragano, M., Kurotaki, Y., Nakanishi, U., & Tokuraku, K. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21176031 · Cited by 16 · see citing works

Effects of NK-4 in a Transgenic Mouse Model of Alzheimer's Disease

Ohta, H., Arai, S., Akita, K., Ohta, T., & Fukuda, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030007 · Cited by 16 · see citing works

An anti-CRF antibody suppresses the HPA axis and reverses stress-induced phenotypes

Futch, H. S., McFarland, K. N., Moore, B. D., Kuhn, M. Z., Giasson, B. I., Ladd, T. B., Scott, K. A., Shapiro, M. R., Nosacka, R. L., Goodwin, M. S., et al. (2019) · The Journal of Experimental Medicine · doi:10.1084/jem.20190430 · Cited by 16 · see citing works

Impact of amyloid β aggregate maturation on antibody treatment in APP23 mice

Balakrishnan, K., Upadhaya, A. R., Steinmetz, J. L., Reichwald, J., Abramowski, D., Fändrich, M., Kumar, S., Yamaguchi, H., Walter, J., Staufenbiel, M., et al. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0217-z · Cited by 15 · see citing works

Rapid Cerebral Amyloid Binding by Aβ Antibodies Infused into β-Amyloid Precursor Protein Transgenic Mice

Winkler, D. T., Abramowski, D., Danner, S., Zurini, M. G. M., Paganetti, P., Tolnay, M., & Staufenbiel, M. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.030 · Cited by 14 · see citing works

De la sérothérapie aux anticorps recombinants « nus »

Watier, H. (2009) · médecine/sciences · doi:10.1051/medsci/20092512999 · Cited by 13 · see citing works

Human Anti-Aβ IgGs Target Conformational Epitopes on Synthetic Dimer Assemblies and the AD Brain-Derived Peptide

Welzel, A. T., Williams, A. D., McWilliams‐Koeppen, H. P., Acero, L. F., Weber, A., Blinder, V., Mably, A. J., Bunk, S., Hermann, C., Farrell, M. A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050317 · Cited by 13 · see citing works

Comprehensive evaluation of human-derived anti-poly-GA antibodies in cellular and animal models of C9orf72 disease

Jambeau, M., Meyer, K. D., Hruška-Plocháň, M., Tabet, R., Lee, C.-Z., Ray-Soni, A., Aguilar, C., Savage, K., Mishra, N., Cavegn, N., et al. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2123487119 · Cited by 11 · see citing works

Crossing Barriers: Advancements in Macromolecular Therapeutics for Neurodegenerative Diseases and Strategies to Overcome the Blood–Brain Barrier

Alo, B., & Lamers, C. (2025) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.5c00153 · Cited by 10 · see citing works

Deficits in hippocampal‐dependent transfer generalization learning accompany synaptic dysfunction in a mouse model of amyloidosis

Montgomery, K. S., Edwards, G. A., Levites, Y., Kumar, A., Myers, C. E., Gluck, M. A., Setlow, B., & Bizon, J. L. (2015) · Hippocampus · doi:10.1002/hipo.22535 · Cited by 10 · see citing works

Preclinical Comparison of the Amyloid-β Radioligands [11C]Pittsburgh compound B and [18F]florbetaben in Aged APPPS1-21 and BRI1-42 Mouse Models of Cerebral Amyloidosis

Waldron, A., Verhaeghe, J. A. J., Wyffels, L., Schmidt, M. E., Langlois, X., der Linden, A. V., Stroobants, S. G., & Staelens, S. G. (2015) · Molecular Imaging and Biology · doi:10.1007/s11307-015-0833-9 · Cited by 8 · see citing works

Development of a novel radioimmunoassay to detect autoantibodies to amyloid beta peptides in the presence of a cross-reactive therapeutic antibody

Sloan, J. H., Ackermann, B. J., O’Dell, M., Bowsher, R. R., Dean, R. A., & Konrad, R. J. (2011) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2011.08.006 · Cited by 7 · see citing works

Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy

Levites, Y., Funk, C. C., Wang, X., Chakrabarty, P., McFarland, K. N., Bramblett, B., O’Neal, V., Liu, X., Ladd, T. B., Robinson, M., et al. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00453-4 · Cited by 6 · see citing works

Clinical Trials for Disease‐Modifying Drugs Such as BACE Inhibitors

Hsu, H. H. (2010) · Wiley eBooks · doi:10.1002/9780470594087.ch9 · Cited by 6 · see citing works

P4–291: Anti–Abeta immunotherapy: Quantitative evaluation of acute effects in young TG2576 mice

Levites, Y., Das, P., Smithson, L. A., & Golde, T. E. (2006) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2006.05.2030

Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease

DeMattos, R. B., Bales, K. R., Cummins, D. J., Dodart, J.-C., Paul, S. M., & Holtzman, D. M. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151261398 · Cited by 1,298 · see citing works

Aβ Immunotherapy: Intracerebral Sequestration of Aβ by an Anti-Aβ Monoclonal Antibody 266 with High Affinity to Soluble Aβ

Yamada, K., Yabuki, C., Seubert, P., Schenk, D., Hori, Y., Ohtsuki, S., Terasaki, T., Hashimoto, T., & Iwatsubo, T. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2021-09.2009 · Cited by 117 · see citing works

Quantitative and Mechanistic Studies of A&amp;#946; Immunotherapy

Golde, T., Das, P., & Levites, Y. (2009) · CNS &amp; Neurological Disorders - Drug Targets · doi:10.2174/187152709787601830 · Cited by 46 · see citing works

Effects of a Peripheral Anti-Aβ Antibody on Plasma and CNS Aβ Clearance

Holtzman, D. M., Bales, K. R., Paul, S. M., & Demattos, R. B. (2003) · Springer eBooks · doi:10.1007/978-3-642-59332-1_8 · Cited by 1 · see citing works